Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01598272 · ClinicalTrials.gov registry record · Phase 4

Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women

A Phase 4 study, sponsored by Pharmanex.

Completed
Registry status
Phase 4
Development phase
95
Enrollment target

NCT01598272: Completed Phase 4 study, sponsored by Pharmanex.

NCT01598272 is a Phase 4 study that has completed, run by Pharmanex. The registered enrollment target is 95 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01598272, a Phase 4 study, has completed, sponsored by Pharmanex.

COMPLETED
Registry status
Phase 4
Development phase
95 participants
Enrollment target

Study Summary

Determine the effects of 8 week Investigational Supplement on cellular detoxification and gene expression profiles

Primary Outcome

Gene Expression Panel (microarray PBMCs), Inflammatory Panel, Oxidative stress Markers-including glutathione panel and F2 isoprostane, Anti-oxidant panel, and Lipid Panel

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Vitality product AM + Vitality product PM

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2011-07
Est. Completion 2012-06
Phase Phase 4
Pharmanex

13 total trials

What the finished NCT01598272 record still lists

NCT01598272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01598272 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01598272 about?

NCT01598272 is a clinical study titled "Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women". Determine the effects of 8 week Investigational Supplement on cellular detoxification and gene expression profiles

What is the current status of trial NCT01598272?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 95 participants. The study started on 2011-07. Estimated completion is 2012-06.

What interventions are being tested in trial NCT01598272?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Vitality product AM + Vitality product PM (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01598272?

This trial is sponsored by Pharmanex, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01598272's enrollment target sits among peer trials

95 869th of 2000 higher than 1,130 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03339128 · 95 participants · Phase 2

    Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

  • NCT03509961 · 95 participants · Phase 2

    The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • NCT03694756 · 95 participants · NA

    TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer

  • NCT04206215 · 95 participants · NA

    Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01598272, the US trial registry maintained by the National Library of Medicine. NCT01598272 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.